Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prestige Brands Makes "Seismic Shift" To OTC With Blacksmith Acquisition

This article was originally published in The Tan Sheet

Executive Summary

On the eve of Blacksmith Brands' one-year anniversary, co-founder and CEO Peter Mann fulfills his promise to cash in on the startup in a $190 million sale to Prestige Brands Holdings, which Mann also helped launch

You may also be interested in...



Prestige Brands Updates PediaCare NDC Information A Year After Sale

The OTC drugs and personal care products company will correct Structured Product Labeling information in the US NDC Directory for PediaCare Children’s Plus Multi-Symptom Cold and Children’s Plus Flu to include one of the products' active ingredient, phenylephrine.

PLx Pharma Proposes “GI-Safer” OTC Aspirin In New Drug Application

The firm files a rare new drug application for an OTC product, a formulation of aspirin and phosphatidylcholine designed to be more tolerable to the gastrointestinal tract. The involvement of OTC veterans Peter Mann and Michael Valentino on PLx’s board suggests strong market potential.

PLx Pharma Proposes “GI-Safer” OTC Aspirin In New Drug Application

The firm files a rare new drug application for an OTC product, a formulation of aspirin and phosphatidylcholine designed to be more tolerable to the gastrointestinal tract. The involvement of OTC veterans Peter Mann and Michael Valentino on PLx’s board suggests strong market potential.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel